Business Context and Reporting Period
Company: Hemispherx Biopharma, Inc. (Note: Input metadata referenced "AIM Immunotech Inc.", but the filing text identifies the registrant as Hemispherx Biopharma, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: February 19, 2009
Reporting Period: Event-based report regarding regulatory status.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on a regulatory event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- FDA Review Extension: The U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application (NDA) of Ampligen(R) (Poly I:Poly C12U).
- Timeline Change: The decision date was moved from February 25, 2009, to May 25, 2009 (a three-month extension).
- Reason for Extension: The extension was requested "in order to provide time for a full review of the submission" following the receipt of additional data within three months of the original goal date.
Guidance, Outlook, and Risks
- Management Commentary: The company notes that extensions are a separate category of FDA response distinct from a complete response letter or approval. The delay is attributed to FDA constraints, including increased workload from the FDA Amendments Act (FDAAA) and Safety First/Safe Use initiatives.
- Product Status: Ampligen(R) is designated as an Orphan Drug for Chronic Fatigue Syndrome (CFS), a condition with no currently FDA-approved treatments. It holds Emergency (compassionate) Cost Recovery Sales Authorization.
- Risks and Contingencies:
- Forward-looking statements regarding the NDA filing do not imply that Ampligen(R) will ever be approved commercially.
- Investigational drugs are experimental and not designated safe and effective for general use by regulatory authorities.
- Strategies involve risks of competition, changing market conditions, and regulatory changes.
Investor Verification Checklist
- Verify the new PDUFA decision date of May 25, 2009, for the Ampligen(R) NDA.
- Confirm the specific additional data submitted to the FDA that necessitated the review extension.
- Review the company's cash runway given the delay in potential commercialization of Ampligen(R).
- Assess the impact of the FDA Amendments Act (FDAAA) on the company's other pipeline candidates.
- Clarify the discrepancy between the metadata company name ("AIM Immunotech Inc.") and the filing registrant ("Hemispherx Biopharma, Inc.").